Satellite Symposium at ACTRIMS 2016

Live Satellite Symposium
at the ACTRIMS Forum 2016

Implementing B-Cell Based Therapeutic Science to Improve Outcomes for Your Patients with Multiple Sclerosis: What Every Neurologist Needs to Know


February 18, 2016


Hyatt Regency New Orleans, 601 Loyola Ave.
New Orleans, LA 70113
Now Open


Recent advances in the understanding of the role of B-cell science, inflammation, CD20 inhibition, and novel therapeutic interventions have presented some very exciting opportunities to improve outcomes in patients with multiple sclerosis. Recent clinical trial data with B-cell based therapies has shown significant benefits for patients with relapsing-remitting and primary progressive multiple sclerosis. This CME activity will review the new science and therapeutic options, including patient selection, the rationale for early intervention, strategies to minimize disease progression and adverse events to improve patient adherence to therapy.

The information presented in this program will help you better manage your patients with multiple sclerosis.

Target Audience

Neurologists, and other healthcare professionals who care for patients with MS.

Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Review the science of B-cell based therapeutics, CD-20 inhibition, and the suppression of inflammation for patients with multiple sclerosis.
  2. Analyze the current efficacy and safety clinical trial data for B-cell based therapeutics for the management of patients with relapsing-remitting and primary progressive multiple sclerosis.
  3. Apply early therapeutic intervention to reduce symptoms of ms, delay disease progression, promote neuroprotection, and optimize quality of life.

Registration Fees

This program is free to all learners.


The Celestin Ballroom A-D
Hyatt Regency New Orleans
601 Loyola Avenue
New Orleans, LA 70113


  1. MS Immunopathology Update
    • Panel Discussion
  2. Targeting B-cells as a Therapeutic Option
    • Panel Discussion
  3. The Rationale for Early Pharmacotherapeutic Intervention with a B-cell Directed Therapy
    • Panel Discussion

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity has been supported by an independent educational grant from Genentech, Inc.

CME Inquires/Special Needs

For all CME inquiries or special needs, please contact [email protected]

Provided By

AcademicCME logo

This activity is an independently supported satellite symposium, not included in the formal ACTRIMS Forum 2016 accredited program. CME credit provided by AcademicCME.

Program Chair

Fred D. Lublin, MD

Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York



Amit Bar-Or, MD

Scientific Director of the Clinical Research Unit,
Montreal Neurological Institute
Montreal, Canada

Mark Freedman, MD

Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada


The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) announces its first stand-alone meeting:
ACTRIMS Forum 2016

ACTRIMS Forum 2016 will be held on February 18-20, 2016 at the Hyatt Regency New Orleans in New Orleans, Louisiana, USA. The conference theme is “Progressive MS: Bench to Bedside and Back.” Learn about cutting edge discoveries in the pathogenesis and management of progressive MS from world renowned experts in the field. Discuss advances in the development of serological and imaging markers of MS disease progression. Hear about ongoing clinical trials of neuroprotective, neuroregenerative and immunomodulatory agents in progressive MS.  The conference will be of value to researchers, clinicians, residents, students, postdoctoral fellows and patient advocates who have an interest in the pathogenesis, clinical management and treatment of progressive MS.

For more information: today.